Empagliflozin offers long-term renal protection in Type 2 diabetes

The sodium–glucose cotransporter 2 inhibitor empagliflozin slows renal progression and averts clinical events, shows further analysis of the EMPA-REG OUTCOME trial.
Source: MedWire News - Category: Consumer Health News Tags: Diabetes Source Type: news